Company profile
Amgen
Biotechnology / Immunology
Share price · AMGN
$425.28+100.89 (+31.10%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(27 total)
27Total Assets
16Approved
6Phase 3 / Filed
5Phase 1–2 / Early
15Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer | |
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular Degeneration |
| Approved | Undisclosed / early pipeline | Rheumatoid Arthritis | |
apremilast(Otezla) | Approved | PDE4Small molecule | Psoriatic ArthritisAtopic DermatitisPsoriasis |
Avacopan(Tavneos) | Approved | Complement C5a receptor 1 (C5aR1/CD88)Small molecule | Chronic Kidney Disease |
| Approved | ProteasomeSmall molecule | Multiple Myeloma | |
| Approved | RANKLMonoclonal antibody | Non-Small Cell Lung CancerMultiple MyelomaRheumatoid ArthritisHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
etanercept(Enbrel) | Approved | TNF-alpha · TNF-alpha / TNF-beta (lymphotoxin-alpha)Protein / enzyme therapeutic | Psoriatic ArthritisPsoriasisRheumatoid Arthritis |
Etelcalcetide(Parsabiv) | Approved | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroidPeptide | Chronic Kidney Disease |
Evolocumab(Repatha) | Approved | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Approved | Cyclooxygenase (COX-1/COX-2) plus histamine H2 receptorSmall molecule | Rheumatoid Arthritis | |
Ivabradine(Corlanor) | Approved | If (funny) channelSmall molecule | Heart Failure |
| Approved | Glucocorticoid receptor | Asthma | |
| Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Approved | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.